Mintz On Air

Welcome to our new podcast series In the Boardroom: Practical Advice and Guidance, featuring insights from Mintz Members Steve Osborn, Melanie Levy, and Tom Burton on a wide variety of topics specific to boards. They’ll answer all of your questions related to the “who, what, when, where, and how” of boards.

For decades, Steve, Melanie, and Tom have guided companies from inception to exit and encountered, navigated, and mitigated innumerable board-related issues. From their experiences, you can learn a great deal. Let’s take a listen!

Session 1: Board Basics

Our first session covers the following topics:
• What is a board of directors, when is it formed, and what’s the ‘best’ composition? (Hint: odd numbers are key!)
• Who sits on a board of directors (i.e., founders, investors, and independents), how are they selected, and how does the composition of a board change over time?
• What is NOT a board (e.g., scientific advisors and observers)?
• What are the duties of the board?
• How should boards handle confidential information?
• Client question - How often should boards meet, and what should occur in these meetings? (Second hint: surprises should never occur!)

We hope you enjoy listening. And stay tuned for our next session, which will cover running an effective board meeting!

 

 

 

 

During this episode, Bridgette Keller speaks with Kerlann Flowers, Legal Director and Senior Attorney for Hofstra University School of Law’s Medical-Legal Partnership (MLP), and Mintz Associate Jean Krebs. They discuss the work of the MLP, how the ongoing pandemic has impacted the MLP and its clients, and, in many respects, made collaboration between medical providers and lawyers more important than ever.

The acceleration in the development and use of, and comfort with, telehealth over the past several years has the potential to counteract historical disparities in access to health care. Listen to hear how Andy Ward, Director of the South Boston Collaborative Center, and Kate Steinle, Chief Clinical Officer of Folx Health, are leveraging telehealth to serve their communities.

Our 6th Annual Pharmacy & Pharmaceutical Industry Summit covered how the confluence of the rapid growth of consumer-centered health care, the lingering effects of the COVID-19 pandemic, a focus on equitable access to care, and the new presidential administration are driving change across the industry. Listen to our team discuss key takeaways from the weeklong summit and how industry trends are impacting business practices.

Health regulatory diligence has the ability to make or break a deal. Listen to hear about our team’s firsthand experience in the importance of conducting health regulatory diligence and best practices in preparing for a sell-side transaction.

2021 was a busy year for Mintz’s Health Law team, as they helped clients navigate complex health care transactions. Listen to hear the macro trends our team is seeing in the market, as well as their takeaways from the deals they closed.

The Mintz Health Law team celebrates 2022 by sharing their health law–focused resolutions. Listen to how the team is resolving to apply the lessons learned from the pandemic, their industry insight, and their knowledge of state and federal government priorities and actions to help clients and colleagues thrive in 2022 and beyond.

In this episode of the EXCLUSIVE RIGHTS: Intellectual Property podcast, Mintz patent attorneys Lily Zhang and Alex Trimble, PhD, discuss double patenting, a complicated and sometimes confounding area of patent law. They break it down in layman’s terms even a non-patent attorney can understand. They highlight the risks of, and ways to avoid being hit by, double patenting rejections – and how to overcome them if they arise.

Among other topics, Lily and Alex discuss:

• The two kinds of double patenting – same invention and obviousness-type double patenting (ODP)
• Common scenarios in which ODP arises
• Using terminal disclaimers for overcoming ODP rejections
• The legal ramifications of using terminal disclaimers
• When terminal disclaimers are the right option